USPTO serial 88532843
AFFIMED
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 7, 2021
- Examiner
- ROSEN, BENJAMIN H
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with AFFIMED?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $975
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Heidelberg, DE
Heidelberg, DE
Mannheim, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Shauna M. Wertheim
Shauna M. Wertheim THE MARBURY LAW GROUP, PLLC11800 SUNRISE VALLEY DRIVE15TH FLOORRESTON, VA 20191Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological and biochemical preparations, in particular in form of antibodies, antibody derivatives, binding proteins and peptides for laboratory and experimentation purposes, in particular for conducting experimental assays, other than for medical or veterinary purposes; biological and biochemical diagnostic preparations other than for medical or veterinary purposes, in particular in form of antibodies, antibody derivatives, binding proteins and peptides | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations for cancer and immuno-oncology; biological and biochemical preparations for the treatment of cancer in form of antibodies, antibody derivatives, binding proteins and peptides for medical or veterinary purposes; biological and biochemical preparations in form of bifunctional or multifunctional proteins with binding affinity to immune cells, in particular with binding affinity to T cells and natural killer (NK) cells, in particular for the subsequent targeting of cancer cells; biological and biochemical preparations for diagnostic use for medical or veterinary purposes, in particular in form of antibodies, antibody derivatives, binding proteins and peptides; biological and biochemical preparations for the treatment of cancer in form of antibodies, antibody derivatives, binding proteins and peptides for use within the framework of experimental and medical or veterinary assays; biological and biochemical diagnostic preparations for medical or veterinary use in form of antibodies, antibody derivatives, binding proteins and peptides for use within the framework of medical or veterinary assays | ACTIVE | — |
| 042 | Scientific and technological services, namely, research and design in the field of immuno-therapy, in particular in the field of immuno-oncology; scientific and technological services, namely, research and design in the field of virology; scientific and technological services, namely, research and design in the field of antiinfectives; scientific and technological services, namely, research and design in the field of neurodegenerative diseases; scientific and technological services, namely, research and design in the field of autoimmune diseases; in particular all of the aforesaid services related to the use of antibodies, antibody derivatives, binding proteins and peptides; scientific and technological services, namely, research and design in the field of immunotherapy by means of activating or modulating innate and adaptive immunity, in particular in the field of immune-oncology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Affimed GmbH
- Other trademarks owned by Affimed GmbH
- Other trademarks owned by Affimed GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named AFFIMED
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 6, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 6, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 6, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 7, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 3, 2021 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Sep 23, 2021 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Aug 24, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 24, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 4, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 21, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 20, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 20, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 20, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| May 29, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 29, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 29, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 29, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 29, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 28, 2021 | ALIE | ASSIGNED TO LIE | — |
| Mar 2, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Sep 7, 2020 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Sep 7, 2020 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Sep 7, 2020 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Mar 7, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 7, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 7, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 6, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 5, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 5, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 22, 2019 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 22, 2019 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 22, 2019 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 15, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 1, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 29, 2019 | NWAP | NEW APPLICATION ENTERED | — |